Key Takeaways:
- Dutch biotech startup, Qiagen, is revolutionising the global preanalytic sample preparation market with its cutting-edge technology
- Qiagen provides comprehensive solutions for the collection, stabilisation, purification, handling, and storage of biological samples
- The company boasts a robust portfolio of 500 proprietary consumable products and automated systems for laboratories
- Qiagen has carved out a unique niche in the market with its proficiency in providing both open and target-specific assays
- The future looks promising for the startup as it continues to innovate and push boundaries in the biotechnology industry
Based in Venlo, Limburg, Dutch biotech startup Qiagen is making waves in the global preanalytic sample preparation market. Through its subsidiaries, the company provides technologies and products designed to facilitate preanalytical sample preparation and linked molecular assay solutions. With their groundbreaking solutions, they have also paved the way for key developments in human and veterinary molecular diagnostics.
Qiagen’s sample technologies grant access to the content of biological samples. They provide comprehensive solutions for the handling of any analyte – DNA, RNA, and protein – from any sample, such as blood, bone, and tissue. With these resources at hand, Qiagen acts as an indispensable ally to scientific researchers, aiding in the acquisition and analysis of crucial genetic material.
What sets Qiagen apart from other startups in this field is its dual focus on sample and assay technologies. While the former is used to collect, stabilize, isolate and purify DNA, RNA and proteins from biological samples, the latter involves reagents which facilitate the detection of these purified target analytes. This versatility has established Qiagen as a one-stop-shop of sorts for both sample collection and molecular diagnostics, marking it out as a unique player in the biotechnology industry.
Another defining characteristic of Qiagen is their expansive range of proprietary, consumable products and automated solutions. The company has developed a remarkable portfolio of roughly 500 products, from consumables for sample collection and purification, to automated systems for low, medium, or high throughout scales. This impressive offering is designed to streamline the work of laboratories and enable efficient, high-quality results.
As Qiagen continues to innovate in the biotechnology field, the future appears promising. As the demand for quick, accurate, and efficient sample preparation and molecular testing continues to grow across the healthcare industry, Qiagen is well-positioned to capitalise on these emerging opportunities. With an industry-leading product range and a clear vision for the future, this Dutch startup stands poised to revolutionise both the global preanalytic sample preparation market and the wider biotechnology industry. To stay up-to-date with their progress and learn more about their offerings, visit Qiagen’s official website or follow them on Twitter, Facebook, and LinkedIn.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
